Biobot Surgical Pte. Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Biobot Surgical Pte. Ltd. - overview
Established
2007
Location
Singapore, -, Singapore
Primary Industry
Medical Devices & Equipment
About
Founded in 2007 and based in Singapore, Biobot Surgical Pte. Ltd. is a health tech company that focuses on robotic-assisted percutaneous surgical systems. The company uses technology to improve diagnostic and treatment accuracy for patients.
As of 2022, Sim Kok Hwee is the CEO of the company. The company provides iSR’obot Mona Lisa, urofusion software, urobiopsy software, easel bed mount, and a biopsy kit. The firm's iSR’obot Mona Lisa is a robotic system that performs transperineal MRI-ultrasound fusion targeted prostate biopsy. In April 2026, Biobot Surgical Pte.
Ltd. raised USD 7. 85 million in series C funding from Temasek Holdings. The organization's iSR’obot Mona Lisa 2.
0 is a robotic-assisted percutaneous surgical system that allows clinicians to plan and position needles during image-guided diagnostic and interventional prostate procedures. Biobot Surgical's features include robotic needle guide positioning and depth control, prostate stability with ultrasound probe sheath, dual Cone technology, automated yet flexible biopsy planning, and elastic MRI-ultrasound fusion. The company will use the April 2026 funding to accelerate growth and scale its robotic surgical solutions.
Current Investors
Zicom Group, Shanghai Microport Medbot(Group)Co.,Ltd., ZIG Ventures
Primary Industry
Medical Devices & Equipment
Sub Industries
Surgical Devices, Diagnostic Equipment, Medical Software
Website
www.biobotsurgical.com
Verticals
HealthTech, Robotics
Company Stage
Series C
Total Amount Raised
Subscriber access only
Biobot Surgical Pte. Ltd. - timeline of key events
Biobot Surgical Pte. Ltd. - financials
| Fiscal Year Ended | Jun 30, 2014 | Jun 30, 2015 | Jun 30, 2016 | Jun 30, 2017 | Jun 30, 2018 | Jun 30, 2019 | Jun 30, 2020 | Jun 30, 2021 | Jun 30, 2022 | Jun 30, 2023 | Jun 30, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | 103,725.439 | 124,669.126 | 409,142.286 | 643,352.051 | 790,525.161 | 594,284.194 | 736,041.841 | - | - | - |
| % Revenue Growth (YoY) | - | - | 20.2% | 228.2% | 57.2% | 22.9% | (24.8%) | 23.9% | - | - | - |
| EBITDA (USD) | (298,815.514) | (599,569.226) | (1,498,451.349) | (1,105,817.53) | (1,150,148.516) | (831,675.09) | (740,237.979) | (2,763,216.356) | - | - | - |
| Operating Income (USD) | (650,251.893) | (1,007,347.542) | (1,972,237.209) | (1,640,209.566) | (1,790,374.996) | (1,466,450.662) | (1,438,875.145) | (3,413,446.516) | - | - | - |
| Operating Margin | - | (971.2%) | (1582.0%) | (400.9%) | (278.3%) | (185.5%) | (242.1%) | (463.8%) | - | - | - |
| % EBITDA Margin | - | (578.0%) | (1201.9%) | (270.3%) | (178.8%) | (105.2%) | (124.6%) | (375.4%) | - | - | - |
| NET Income (USD) | (452,592.796) | (585,123.854) | (1,972,544.528) | (1,423,931.322) | (1,925,016.038) | (1,474,221.074) | (1,517,900.134) | (3,602,640.736) | - | - | - |
| % Net Margin | - | (564.1%) | (1582.2%) | (348.0%) | (299.2%) | (186.5%) | (255.4%) | (489.5%) | - | - | - |
Biobot Surgical Pte. Ltd. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.